Itandehui Belem Gallegos Velasco

Dr. Itandehui Belem Gallegos Velasco


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Biosensors
Verified
Journal Article
Open access
PDF file
Christian Perezcampos-MayoralChristian Perezcampos-Mayoral
Christian Perezcampos-Mayoral
JGJaime Gutiérrez Gutiérrez
Jaime Gutiérrez Gutiérrez
Jose Luis Cano PerezJose Luis Cano Perez
Jose Luis Cano Perez
Marciano Vargas TreviñoMarciano Vargas Treviño
Marciano Vargas Treviño
IVItandehui Belem Gallegos Velasco
Itandehui Belem Gallegos Velasco
RRRoberto Rojas-Laguna
Roberto Rojas-Laguna
Vital signs not only reflect essential functions of the human body but also symptoms of a more serious problem within the anatomy; they are well used for physical monitoring, caloric expenditure, and performance before a possible symptom of a massive failure—a great variety of possibilities that together form a first line of basic diagnosis and follow-up on the health and general condition of a person. This review includes a brief theory about fiber optic sensors’ operation and summarizes many research works carried out with them in which their operation and effectiveness are promoted to register some vital sign(s) as a possibility for their use in the medical, health care, and life support fields. The review presents methods and techniques to improve sensitivity in monitoring vital signs, such as the use of doping agents or coatings for optical fiber (OF) that provide stability and resistance to the external factors from which they must be protected in in vivo situations. It has been observed that most of these sensors work with single-mode optical fibers (SMF) in a spectral range of 1550 nm, while only some work in the visible spectrum (Vis); the vast majority, operate through fiber Bragg gratings (FBG), long-period fiber gratings (LPFG), and interferometers. These sensors have brought great advances to the measurement of vital signs, especially with regard to respiratory rate; however, many express the possibility of monitoring other vital signs through mathematical calculations, algorithms, or auxiliary devices. Their advantages due to miniaturization, immunity to electromagnetic interference, and the absence of a power source makes them truly desirable for everyday use at all times.

11 December 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Christian Perezcampos-MayoralChristian Perezcampos-Mayoral
Christian Perezcampos-Mayoral
JGJaime Gutiérrez Gutiérrez
Jaime Gutiérrez Gutiérrez
Jose Luis Cano PerezJose Luis Cano Perez
Jose Luis Cano Perez
Marciano Vargas TreviñoMarciano Vargas Treviño
Marciano Vargas Treviño
LCLorenzo Tepech Carrillo
Lorenzo Tepech Carrillo
RRRoberto Rojas-Laguna
Roberto Rojas-Laguna
We propose and demonstrate a tunable and switchable multi-wavelength fiber ring laser configuration based on a Mach–Zehnder interferometer (MZI) filter. The MZI was fabricated using a core-offset splicing technique, with a 2 cm piece of thin-core erbium-doped fiber (TCEDF), with a core diameter of 2.90 µm, coupled in the central region of the MZI between two segments of single-mode fiber (SMF). By applying curvature to the MZI filter, we generated lasing single-, double-, triple-, and quadruple-emission lines with a curvature range from 2.3452 m−1 to 6.0495 m−1. A single-emission lasing line can be tuned from 1556.63 nm to 1564.25 nm with a tuning span of 7.62 nm and an SMSR of 49.80 dB. The laser emission can be switched to quadruple- and triple-emission lasing signals, with SMSR values of 39.96 dB and 36.83 dB, respectively. The dual-narrow emission lasing signal can be tuned from 1564.56 nm to 1561.34 nm, with an SMSR of 40.46 dB. Another lasing dual-emission signal can be tuned from 1585.69 nm to 1576.89 nm, producing an 8.8 nm tuning range, and from 1572.53 nm to 1563.66 nm, producing an 8.87 nm range, with the best SMSR of 42.35 dB.

29 August 2014 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
Laura Pérez-Campos MayoralLaura Pérez-Campos Mayoral
Laura Pérez-Campos Mayoral
Eduardo Perez-CamposEduardo Perez-Campos
Eduardo Perez-Campos
EZEdgar Zenteno
Edgar Zenteno
AMAbraham Majluf-Cruz
Abraham Majluf-Cruz
EPEduardo Perez-Ortega
Eduardo Perez-Ortega
IVItandehui Belem Gallegos Velasco
Itandehui Belem Gallegos Velasco
Patients with metabolic syndrome (MS) often have increased platelet aggregation. In order to determine which concentration detects a higher level of platelet aggregation in patients with MS, the agonists ADP and epinephrine were compared. The study included 56 subjects with MS and 53 healthy subjects. Blood pressure, weight, body-mass index, and hip-to-waist ratio were collected from all subjects. Insulin, glucose, total serum cholesterol, HDL-C, LDL-C, total triglycerides, markers of plasma atherogenicity, and indices of insulin resistance were measured in all participants. For aggregometry assays, the Born method was used. Platelets were treated with ADP and epinephrine in decreasing concentrations of 2.34, 1.17, and 0.58 μM, as well as, 11.0, 1.1, and 0.55 μM, respectively. ROC curves were plotted to define the diagnostic efficiency of epinephrine levels for MS. Among healthy individuals and MS patients significant differences were observed in body weight, body-mass index, waist-circumference, levels of insulin, indices of insulin resistance, and levels of HDL-cholesterol, LDL-cholesterol and total triglycerides. There was a significant difference in the detection of increased platelet aggregation using 11.0 μM and 0.55 μM epinephrine and 0.58 μM ADP. With both agonists, ROC analysis showed an area under the curve of >0.8 for 11.0 μM epinephrine and 2.34 μM ADP. However, for MS patients, 11.0 μM epinephrine had a slightly better diagnostic efficiency than 2.34 μM ADP. It was found that 11.0 μM epinephrine and 2.34 μM ADP detected better platelet aggregation in patients with MS than in healthy subject. Both concentrations detected increased platelet aggregation in patients with MS.

24 December 2012 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
IVItandehui Belem Gallegos Velasco
Itandehui Belem Gallegos Velasco
Eduardo Perez-CamposEduardo Perez-Campos
Eduardo Perez-Campos
MCMargartito Martinez Cruz
Margartito Martinez Cruz
MMMiguel Ángel Mayoral
Miguel Ángel Mayoral
Laura Pérez-Campos MayoralLaura Pérez-Campos Mayoral
Laura Pérez-Campos Mayoral
PHPedro Hernández
Pedro Hernández
Fibroadenomas are benign human breast tumors, characterized by proliferation of epithelial and stromal components of the terminal ductal unit. They may grow, regress or remain unchanged, as the hormonal environment of the patient changes. Expression of antigen TF in mucin or mucin-type glycoproteins and of galectin-3 seems to contribute to proliferation and transformations events; their expression has been reported in ductal breast cancer and in aggressive tumors.

30 April 2023 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
IVItandehui Belem Gallegos Velasco
Itandehui Belem Gallegos Velasco
PÁPérez-Acevedo Miguel Ángel
Pérez-Acevedo Miguel Ángel
BFBerenice Fernández-Rojas
Berenice Fernández-Rojas
HAHernández-Cruz Pedro Antonio
Hernández-Cruz Pedro Antonio
JHJesus Hernandez-Juarez
Jesus Hernandez-Juarez
Hyperglycemia, insulin resistance, and endothelium dysfunction are related to platelet hyperactivity in type 2 diabetes mellitus (T2D) patients. Glucosamine (GlcN) has inhibitory effects on platelets of animals and healthy donors, but this role in platelets from T2D patients is unknown. The aim of this study was to evaluate the GlcN in vitro effects on platelet aggregation in T2D patients and healthy donors. Donors´ and T2D patients' samples were analyzed through flow cytometry, Western blot, and platelet aggregometry. Platelet aggregation was induced using ADP and thrombin, with or without GlcN, N-Acetyl-glucosamine, galactose, or fucose. GlcN inhibited ADP and thrombin-induced platelet aggregation, while the other carbohydrates did not. GlcN suppressed the second wave of ADP-induced platelet aggregation. No differences in the percent of inhibition of ADP-induced platelet aggregation by GlcN were found between donors and T2D patients, but this effect was significantly higher in healthy donors using thrombin as an agonist. In addition, GlcN increased protein O-GlcNAcylation (O-GlcNAc) in the platelets from T2D patients but not in healthy donors. In conclusion, GlcN inhibited the platelet aggregation induced by ADP and thrombin for both study groups and increased O-GlcNAc in platelets from T2D patients. Further studies are required to evaluate the possible use of GlcN as an antiplatelet agent.